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Abstract
Background: Providing timely access to physiotherapy has long been a problem for the National
Health Service in the United Kingdom. In an attempt to improve access some physiotherapy
services have introduced a new treatment pathway known as PhysioDirect. Physiotherapists offer
initial assessment and advice by telephone, supported by computerised algorithms, and patients are
sent written self-management and exercise advice by post. They are invited for face-to-face
treatment only when necessary. Although several such services have been developed, there is no
robust evidence regarding clinical and cost-effectiveness, nor the acceptability of PhysioDirect.
Methods/Design: This protocol describes a multi-centre pragmatic individually randomised trial,
with nested qualitative research. The aim is to determine the effectiveness, cost-effectiveness, and
acceptability of PhysioDirect compared with usual models of physiotherapy based on patients going
onto a waiting list and receiving face-to-face care. PhysioDirect services will be established in four
areas in England. Adult patients in these areas with musculoskeletal problems who refer themselves
or are referred by a primary care practitioner for physiotherapy will be invited to participate in the
trial. About 1875 consenting patients will be randomised in a 2:1 ratio to PhysioDirect or usual
care. Data about outcome measures will be collected at baseline and 6 weeks and 6 months after
randomisation. The primary outcome is clinical improvement at 6 months; secondary outcomes
include cost, waiting times, time lost from work and usual activities, patient satisfaction and
preference. The impact of PhysioDirect on patients in different age-groups and with different
conditions will also be examined.
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BMC Health Services Research 2009, 9:136 http://www.biomedcentral.com/1472-6963/9/136Incremental cost-effectiveness will be assessed in terms of quality adjusted life years in relation to
cost.
Qualitative methods will be used to explore factors associated with the success or failure of the
service, the acceptability of PhysioDirect to patients and staff, and ways in which the service could
be improved.
Discussion: It is still relatively unusual to evaluate new forms of service delivery using randomised
controlled trials. By combining rigorous trial methods with economic analysis of cost-effectiveness
and qualitative research this study will provide robust evidence to inform decisions about the
widespread introduction of PhysioDirect services.
Trial registration: Current Controlled Trials ISRCTN55666618
Background
The scale of the problem
Musculoskeletal problems are very common, accounting
for 15% of all consultations with general practitioners
(GPs) in the United Kingdom (UK) [1]. Many of these
patients are referred to physiotherapists, with 4.4 million
new referrals to physiotherapy being made each year [2].
Ensuring timely access to physiotherapy has long been an
issue within the NHS, with waiting times for treatment of
several months in some areas. This is a problem for
patients, because musculoskeletal conditions cause pain
and disability, and for the economy because these condi-
tions are second only to mental health problems as a
cause of days lost from work. In particular, back pain
accounts for some 120 million days of certified absence
from work each year and half of all patients with back
pain who are off work for more than 6 months never
return to employment [3]. Delayed access to physiother-
apy is also a problem for the NHS because when patients
are finally offered a physiotherapy appointment many fail
to attend, and in other cases patients wait a long time for
a physiotherapy consultation when it is unlikely that this
will offer benefit, so much of the current physiotherapy
resource is used inefficiently and ineffectively.
PhysioDirect as a new way of improving access to care
In response to these problems, several areas in the UK
have introduced a new form of treatment pathway, known
as 'PhysioDirect'. In this approach, patients seeking phys-
iotherapy are invited to telephone a physiotherapist for an
initial assessment and advice, following which the patient
is posted written self-management and exercise advice.
Patients are invited for a face-to-face consultation if the
initial telephone assessment establishes that this is neces-
sary or if the patient does not get better after following the
initial advice.
PhysioDirect is based on a physiotherapist following a
computerised algorithm to assess the patient in a struc-
tured way, and offering appropriate written advice. This
reflects a wider trend to explore the use of this type of tech-
nology in health care, exemplified by the development of
NHS Direct within the UK. Although there is little evi-
dence about the role of telephone assessment in the con-
text of physiotherapy, research on the use of telephone
triage systems in other clinical settings has shown that it is
safe, clinically accurate, cost-effective, acceptable to
patients, and reduces the workload of clinicians [4-7].
The effectiveness of physiotherapy
Research about the effectiveness of alternative approaches
to provision of physiotherapy services needs to take
account of the evidence about the effectiveness of differ-
ent forms of physiotherapy in different conditions. For
some conditions (for example acute low back pain) it
appears that manual physiotherapy offers little benefit
over simple advice. In conditions such as chronic back
pain, promoting exercise appears to be effective [8-11],
while systematic reviews about the effectiveness of manip-
ulation have reached inconsistent conclusions [12,13].
Importantly, recent trials have shown that a single session
of advice from a physiotherapist is as effective as a course
of routine physiotherapy for patients with mild to moder-
ate back problems [14,15] Similarly, several recent trials
have shown that physiotherapy-led advice and exercise
are effective in knee pain [11,16,17]. On the other hand,
for some other conditions such as neck pain and shoulder
pain there is evidence that adding manual physiotherapy
interventions to advice and exercise is more effective than
advice and exercise alone [18-20].
In summary, it is becoming clear that for some conditions
patients may benefit from physical treatment such as exer-
cise and manual therapy from a physiotherapist, for other
conditions it is equally effective and may be cheaper to
provide brief advice about self-management and exercise,
and in some situations physical treatments from physio-
therapists have little to offer. Therefore the concept of an
approach which provides assessment, advice and triage
initially and reserves more intensive (and expensive)
treatments for those who do not improve may be the most
cost-effective strategy. This is analogous to the 'steppedPage 2 of 11
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of conditions, for example mental health, where there is a
high level of demand and a need to target resources. In the
context of physiotherapy, this approach could reduce
costs for patients and for the NHS, provide earlier advice
for all patients and physical treatment more quickly for
those who may benefit from it (by screening out those
unlikely to benefit from it), and be more convenient and
accessible for patients as a whole.
Is faster access beneficial?
The drive to provide faster access to physiotherapy is pred-
icated on the assumption that providing treatment at an
earlier stage is beneficial compared with delayed treat-
ment. There is evidence from several studies that early
physiotherapy intervention in some situations provides
faster symptom relief, improves quality of life, reduces
absenteeism, leads to a reduction in physician consulta-
tions, and is more cost-effective [21-24].
Existing evidence about PhysioDirect
Local evaluations and one small trial of PhysioDirect sug-
gest that services based on telephone advice given by
physiotherapists are likely to be popular with patients
[25], although there is no evidence about costs or out-
comes, or the important issue of safety. Audits in the pio-
neering services in Cheltenham and Huntingdonshire
suggested that 40–60% of patients referred by GPs to
physiotherapy can be managed by telephone alone with-
out a face-to-face consultation, telephone consultations
take approximately half as long as face-to-face consulta-
tions, waiting times for a face-to-face appointment were
reduced from four weeks to 10 days and 'did-not-attend'
(DNA) appointment rates were reduced from 15% to 1%.
Patients were very satisfied with the service, with 80% rat-
ing it as good or excellent [25-27]. These findings demon-
strate the potential benefits of PhysioDirect, but the lack
of comparative data from concurrent controls, and a lack
of robust data about clinical outcomes and costs, means
that there is insufficient evidence currently available to
justify the widespread implementation of this new way of
working.
Research questions
This paper describes the protocol for a randomised con-
trolled trial of 'PhysioDirect' versus usual care based on
patients going onto a waiting list for a face-to-face
appointment.
The research questions are:
• Is PhysioDirect at least as effective as usual models of
physiotherapy based on patients going onto a waiting
list for face-to-face physiotherapy?
• What is the cost-effectiveness of PhysioDirect com-
pared with usual care?
• Do patients prefer PhysioDirect services rather than
usual care; do they find PhysioDirect more convenient
and does it address their perceived needs?
• What are the health outcomes and experiences of dif-
ferent groups of patients (those in different age groups
and with different types of problems) when referred to
PhysioDirect rather than usual care?
Methods
Study design
The study consists of an individually randomised prag-
matic randomised controlled trial with two parallel
groups, incorporating economic evaluation and nested
qualitative research. The comparison is between patients
randomised to a service based on initial telephone assess-
ment and advice from PhysioDirect, followed by face-to-
face treatment when necessary, versus usual care consist-
ing of allocation to a waiting list followed by face-to-face
care for all patients.
Setting
PhysioDirect services will be newly established in four
areas of England. Each physiotherapy service will provide
care for patients from a defined group of practices within
one of the following Primary Care Trusts (PCTs): Bristol,
Somerset, Stoke-on-Trent, Central and Eastern Cheshire
PCT. The total population covered across all four PCTs
will be about 625,000 people. The existing physiotherapy
services received about 18,300 referrals from primary care
professionals in these practices in 2008.
Participants
The inclusion criteria are as broad as possible in order to
maximise generalisability and to reflect the 'real-world'
operation of PhysioDirect services. Inclusion criteria are
adults (aged 18 years or over) who are referred by GPs or
other members of the primary health care team, or who
refer themselves (self-referred) for musculoskeletal physi-
otherapy.
Exclusion criteria are children (< 18 years); patients
referred to physiotherapy by a hospital consultant, emer-
gency department or primary/secondary care interface
service; those needing domiciliary physiotherapy; those
needing post-operative physiotherapy; those needing
physiotherapy for non-musculoskeletal problems; those
unable to communicate by telephone in English.
GPs or health care professionals in the relevant practices
will refer patients to physiotherapy in their usual way, orPage 3 of 11
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screened by a senior physiotherapist within one working
day to confirm that the patient is potentially eligible, and
eligible patients will be sent information about the trial by
post, along with a consent form and a baseline question-
naire. Patients who give consent to participate and com-
plete the baseline questionnaires will be randomised in a
2:1 ratio to PhysioDirect or usual care. This allocation
ratio was chosen to ensure that sufficient people are ran-
domised to PhysioDirect to make it viable to establish this
new service, given that non-consenting and excluded
patients will continue to receive usual care as well as those
randomised to usual care. Randomisation will be under-
taken using web or telephone access to a secure remote
allocation system, with allocation made at the level of the
individual, minimising by PCT, gender, patient age group
and presenting complaint. Following randomisation,
patients will be sent a letter either inviting them to contact
PhysioDirect and telling them how to do so (intervention
arm), or telling them that they are on a waiting list for a
face-to-face appointment (control arm).
The number of patients excluded from the trial for differ-
ent reasons will be recorded. The age and sex of all
patients will be recorded in anonymised form, to make it
possible to compare participating and non-participating
populations. Eligible patients who decline to participate
will receive usual care.
Description of intervention and control arms
Intervention
'PhysioDirect'. As soon as possible after consent to partic-
ipate in the trial is received the patient will be invited to
telephone a senior physiotherapist for initial assessment
and advice. The physiotherapist will follow a computer-
ised algorithm (as developed by the PhysioDirect service
in Huntingdonshire) to assess the patient and record find-
ings. In most cases, at the end of the consultation the
physiotherapist will post a relevant advice leaflet about
self-management and exercises to the patient, inviting
them to phone back to report progress after about 2 to 4
weeks if appropriate. At that point they can be given fur-
ther advice or be booked for a face-to-face consultation if
necessary. Alternatively, the initial phone call may estab-
lish that more urgent face-to-face care is needed, in which
case this will be booked at the outset, or the assessment
may establish that physiotherapy is unlikely to be effective
and the patient can be given appropriate advice and dis-
charged. In this way those patients most likely to benefit
from face-to-face physiotherapy should be able to receive
it more quickly, hopefully leading to a faster improve-
ment and a quicker return to work and usual activities.
All four physiotherapy services participating in this trial
will set up a PhysioDirect service following the same
model of organisation and using the same assessment
software, as developed in Huntingdonshire. All physio-
therapists operating the PhysioDirect services will under-
take a structured training programme and be assessed and
certified as competent to undertake PhysioDirect before
they assess patients in the trial. Training and assessment of
competency will be undertaken by PhysioDirect trainers
from Huntingdon PCT. In this way, we will seek to ensure
consistency in the way the intervention is developed in
each service. Each PhysioDirect service will have a run-in
period of at least two months to ensure smooth running
of the service before patients to be included in the trial are
recruited.
Control
Usual care involves patients being referred by a GP or
other member of the primary health care team to a physi-
otherapist. In some areas, patients may also refer them-
selves directly. Patients go onto a waiting list for an initial
face-to-face physiotherapy assessment and then usually
have a series of follow-up treatment appointments for sev-
eral weeks or months. The waiting time may differ consid-
erably at different services, at different sites providing
physiotherapy within one service, and at different times of
year.
Outcome assessment
Outcomes will be assessed at baseline, and at 6 weeks and
6 months after randomisation.
The primary outcome is clinical outcome at 6 months,
assessed using the physical component summary (PCS)
measure from the SF-36v2 questionnaire [28]. The SF-
36v2 PCS is a well recognised generic measure of health
status. It is particularly suitable for this trial because,
unlike disease specific measures, it is applicable to the
wide range of musculoskeletal problems referred to phys-
iotherapy.
Two further measures of clinical outcome will be used and
considered as important secondary outcomes. The first is
the MYMOP2 [29] questionnaire, which is a patient gen-
erated measure. It allows patients to specify up to two
symptoms and one functional limitation for which they
have been referred to physiotherapy, and follow-up ques-
tionnaires assess change in those specific symptoms/limi-
tations. This individualised and validated measure can
also be used by patients with a wide range of problems
[29]. Secondly, a single question will be included as a glo-
bal measure of individual perception of overall improve-
ment (based on a seven point Likert scale from 'very much
worse' to 'very much better'). This type of global improve-
ment score is recommended by the Outcomes Measures in
Rheumatology Clinical Trials- Osteoarthritis Research
Society International (OMERACT-OARSI) initiative [30].Page 4 of 11
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• costs
• quality of life (measured using the EQ5D measure
[31]
• the individual scales and the mental component
summary measure from the SF-36
• waiting times for treatment
• time lost from work and usual activities
• satisfaction with care provided
• preference for telephone or face-to-face assessment.
Collection of data
The baseline questionnaire will collect data about patient
characteristics and about the outcome measures. Data
about outcomes at follow-up will be collected from postal
questionnaires sent at 6 weeks and 6 months after ran-
domisation. Data will be collected by telephone instead of
post where patients do not respond to a postal question-
naire or a postal reminder, where patients express a pref-
erence for telephone administration, or where patients are
unable to complete written questionnaires in English.
Data about use of healthcare resources will be extracted
from physiotherapy service records and medical records,
and details of use of other resources will come from the
patient questionnaires.
Table 1 lists the various outcome measures, the timing of
data collection and the source of the data.
Economic evaluation
The economic evaluation will be carried out from three
perspectives. Costs to the NHS will include the cost of pro-
viding physiotherapy plus any other costs related to treat-
ing the condition for which the patient has been referred
to the physiotherapy service. These include: primary care
consultations, treatments and investigations, medication,
secondary care consultations, and inpatient care. Set-up
costs associated with the service will also be collected.
Patient and companion costs will include: travel, depend-
ent carer costs, private treatment, over-the-counter medi-
cation, and loss of earnings. Societal costs will include use
of social services, disability payments, and time off work.
Data will be obtained from four main sources: the patient
self-completion questionnaires at baseline, 6 weeks and 6
months after randomisation; primary care patient records;
patient records at the physiotherapy services; and records
kept as part of the trial detailing length of consultation,
grade of staff, and amount of non-contact time. A time
and motion study will be conducted to observe activities
during non-contact time to estimate the opportunity cost
of that time.
Curtis [32] will be used to value primary and community
care consultations. Primary care investigations will be val-
ued at cost; the Department of Health tariff will be used
for A&E visits, out-patient visits and investigations, and
inpatient stays; and the British National Formulary will be
used to cost prescribed medication. Most patient and carer
costs will be directly reported; the AA schedule for valuing
mileage will be used to cost car journeys Time off work by
patients and carers will be valued using patient-level
information on how absenteeism is dealt with by employ-
ers, and will adopt the friction approach, which includes
only the resources required to replace the employee [33].
There will be no need to discount costs or outcomes, as
they will cover a period of less than one year.
Process evaluation
Process data about the physiotherapy services provided
will include: the number, type and duration of consulta-
tions with physiotherapists; rates of non-attended
appointments with physiotherapists; and the qualifica-
tions and experience of all the physiotherapists involved
at all four sites. Complaints and adverse events relating to
the physiotherapy services will be systematically recorded
and investigated.
Qualitative research
Qualitative research will be conducted alongside the trial
to study issues of implementation and to understand the
key barriers and facilitators to the success of a PhysioDi-
rect service. The qualitative research will also examine the
acceptability of the service and identify the factors (organ-
isational, professional and patient related) which influ-
ence its implementation. The interviews will be
conducted in person or by telephone and longitudinal
data collection will allow themes to be followed up with
participants over time.
Interviews will be carried out with a purposive sample of
40–60 patients to explore the accessibility of the service,
the value, acceptability and influence of telephone and
face-to-face care, and how services could be improved.
Participants in the interviews will be selected to ensure a
diverse sample based on age, gender, ethnicity and pre-
senting clinical problem in order to get the widest range of
opinions and experiences.
Interviews with a purposive sample of between 20–30 key
informants (physiotherapists, GPs, practice-based com-
missioning leads and managers) will address contextual
factors that act to facilitate or hinder the use and imple-Page 5 of 11
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Table 1: Outcome measures, timing of data collection and source of data
Timing Source
Patient identifiers, type of problem, age and sex Pre-consent Referral letter. Recorded (anonymised) in 
research database
Demographic details Baseline Baseline patient questionnaire
SF36v2 Baseline, 6 weeks, 6 months Patient questionnaires
MYMOP Baseline, 6 weeks, 6 months Patient questionnaires
EQ5D Baseline, 6 weeks, 6 months Patient questionnaires
Overall perception of improvement 6 weeks, 6 months Patient questionnaires
Time lost from work and usual activities Baseline, 6 weeks, 6 months Patient questionnaires
Satisfaction with care provided 6 weeks, 6 months Patient questionnaire
Preference for Physiodirect or usual care Baseline, 6 months Patient questionnaires
Waiting time for treatment Collected at end of study Physiotherapy service records, from date of 
referral received to date first phone or face-to-
face consultation
Patient and companion costs 6 weeks, 6 months Patient questionnaires
Cost of lost production associated with time 
off work and usual activities.
6 weeks, 6 months Estimated from information in patient 
questionnaires
Costs of providing physiotherapy Set up costs: collected during set up phase and 
once the service is operating.
Treatment over 6 months: collected at end of 
study.
Set up: data from PCTs about resources 
involved in setting up the service; Treatment: 
physiotherapy records, data collected within 
the trial about lengths of consultations, staff use 
of time, staff grades etc.
Costs in general practice 
(consultations, treatments, investigations)
Collected at end of study, from randomisation 
to 6 months
Patients GP records, consultations costed using 
Netten and Curtis and NHS reference costs 
for other costs
Costs of prescriptions Collected at end of study, from randomisation 
to 6 months
Patients GP records, costed using British 
National Formulary
NHS secondary care costs 
(outpatients, inpatients, admissions)
6 weeks, 6 months Patient questionnaires for resource use, costed 
using NHS tariffs
Process evaluation: number, type & duration of 
consultations with physiotherapists; non-
attended appointments with physiotherapists.
Collected throughout study from 
randomisation to 6 months
Physiotherapy records
Qualifications and experience of 
physiotherapists.
Collected at the beginning of the study Online questionnaire completed by 
physiotherapists
Complaints and adverse events Collected throughout study from 
randomisation to 6 months
Notified by patients, physiotherapy services, 
general practices or any other sources.
BMC Health Services Research 2009, 9:136 http://www.biomedcentral.com/1472-6963/9/136mentation of PhysioDirect or usual physiotherapy serv-
ices, or that influence outcomes, and the perceived value
of the services.
Ethics
Ethical approval for this study has been obtained from
Southmead Research Ethics Committee, reference 08/
H0102/95.
Trial registration
Current Controlled Trials ISRCTN55666618
Analysis
The main hypotheses are that PhysioDirect will be clini-
cally equivalent to usual care and more cost-effective at 6
months after randomisation.
Analysis and presentation of data will be in accordance
with CONSORT guidelines. The primary analysis will
employ multivariable regression to investigate between-
group differences in mean SF-36 PCS score at six months
follow up. The primary analysis will be conducted on an
intention-to-treat (ITT) basis, with due emphasis placed
on the confidence interval for the between-arm compari-
son when inferring equivalence (or otherwise) of the two
groups. Clinical equivalence between the arms will only
be concluded if the 95% confidence interval for the pri-
mary outcome lies wholly inside the range -0.2 to 0.2 SDs.
Given the equivalence design and the generally conserva-
tive nature of ITT analysis, between-group differences will
also be investigated using methods that model compli-
ance with the allocated treatment arm, such as instrumen-
tal variable regression. Analyses will adjust for
minimisation variables and baseline outcome variable
scores, and will take appropriate account of the hierarchi-
cal nature of the data (practice and physiotherapy site).
In the economic analysis mean cost to the NHS per patient
in each arm will be compared with mean gain in quality
adjusted life year (QALY) using the EQ5D in order to esti-
mate a cost-utility ratio of incremental cost per QALY
gain. Secondary analysis will explore the QALY gain using
the SF-6D [34], derived from the SF-36. A cost-conse-
quences matrix will be used to present a comparison of
cost per patient in each group from the patient and soci-
etal perspectives with a range of outcomes, for example,
personal perception of improvement and patient satisfac-
tion. The effect of uncertainty in unit cost estimates or
assumptions about resource use will be addressed in sen-
sitivity analyses. Using a bootstrapping approach for data
analysis, the results of the economic analysis will be pre-
sented using cost-effectiveness acceptability curves.
Secondary analyses
are summarised in Table 2.
Sub-group analyses
Appropriate interaction terms will be entered into the pri-
mary regression analysis for SF-36 in order to conduct pre-
specified subgroup analyses according to presenting com-
plaint, patient age-group, socio-economic status and PCT.
Since the trial is powered to detect overall equivalence
between the groups rather than interactions of this kind,
the results of these essentially exploratory analyses will be
presented using descriptive statistics and, where helpful,
confidence intervals as well as p-values, and interpreted
with due caution.
Table 2: Secondary analyses:
(1) Assessing equivalence in clinical outcome using the MYMOP2 score.
(2) Examining clinical outcome at 6 weeks using the SF-36 PCS
(3) Comparing the proportion of patients who 'respond to treatment' in each arm, in line with the Outcomes Measures in Rheumatology Clinical 
Trials- Osteoarthritis Research Society International (OMERACT-OARSI) recommendations [30], using the SF-36 physical function and bodily 
pain scales and the global improvement score
(4) Repeating the primary analysis adjusting also for any variables exhibiting marked imbalance at baseline to check that this does not influence the 
findings
(5) Analyses as above for secondary outcomes (where p-values will be adjusted to account for multiple testing)
(6) Investigating the effectiveness and cost-effectiveness of PhysioDirect for patients of different age-groups, or with different presenting 
problems
(7) Investigating the effectiveness and cost-effectiveness of PhysioDirect in each of the four PCTs, in exploratory sub-group analyses
(8) Investigation of process measures such as physiotherapy consultation rates, physiotherapy 'did-not-attend' rates and consultation rates with 
other health care services in the NHS and private sectorsPage 7 of 11
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outcomes, some of the outcomes will be strongly clus-
tered by physiotherapy site (particularly waiting times).
The analysis of these outcomes will be descriptive only.
Qualitative analysis
Analysis of the qualitative data will use an inductive, the-
matic approach based on the method of constant compar-
ison. Data collection and analysis will be carried out
iteratively so that emerging themes in the analysis can be
explored in depth in further interviews. Sampling will
continue until no new themes emerge. A researcher will
code the transcribed data, with a sample of interviews
being independently coded by a second researcher to
ensure transparency and agree emergent themes at succes-
sive stages of the data collection and analysis. Negative or
deviant cases will be investigated closely.
Sample size and power calculations
This study is powered to establish clinical equivalence
using the PCS scale from the SF-36. The minimum clini-
cally important difference in a range of populations and
conditions has been estimated as being at least 4 points
(0.4 SD) [35-38]. However in this study a difference of no
greater than 2 points has been specified as demonstrating
equivalence. This is equivalent to an effect size of 0.2,
which is considered a small effect size [38]. Sample sizes
for analysis of 488 and 976 in the Usual Care and Physio-
Direct groups respectively will yield 80–95% power to
reject a null hypothesis of non-equivalence with an over-
all alpha of 0.05 alpha assuming that the observed differ-
ence in means is in the range zero to 0.045 SDs. The target
sample size for patients completing the final six-month
follow-up questionnaire is 1000 patients in the PhysioDi-
rect arm and 500 patients in the Usual Care arm.
Assuming 20% non-collection of the primary outcomes, it
will be necessary to recruit 1250 and 625 patients in the
PhysioDirect and usual care arms respectively, or 1875
patients in total.
Discussion
The use of a randomised controlled trial to evaluate a 
service innovation
Changes in the organisation and delivery of health serv-
ices affect large numbers of people. Relatively small differ-
ences in outcome or cost at an individual level can have a
big impact at a population level and major financial con-
sequences for the health care system. Despite these con-
siderations, many innovations in health care delivery are
implemented based on very limited evidence about costs
or effects. This trial represents a relatively unusual exam-
ple of a large multi-centre randomised controlled trial
designed to provide rigorous evidence about the costs and
benefits of a new approach to service delivery. Embedding
a trial within routine services, in the context of many other
pressures on managers and staff, is challenging. The
design of the study also raised a number of important
methodological issues as described below.
Level of randomisation
When interventions are designed at the level of an organ-
isation it is often most appropriate to randomise patients
in clusters by organisation rather than individually. This is
in order to avoid problems of contamination, with
patients within the same service receiving different treat-
ments. However for a study of this type, involving a small
number of services, cluster randomisation would require
a much larger sample size in what is already a large trial.
It also raises difficulties in relation to informed consent,
and may lead to bias due to differential recruitment rates
between patients invited to the intervention or control
arms. In this study, it is possible to randomise patients
individually with little risk of contamination. However,
individual randomisation makes it difficult to assess some
outcomes (such as waiting times) which are affected by
the existence of two treatment pathways within one
organisation. The research team will give particular atten-
tion to maintaining separate waiting lists for patients in
the PhysioDirect and usual care arms, and allocating
equivalent levels of physiotherapy resources to patients in
each group, but caution will be needed in interpreting
findings about these organisational outcomes.
Establishing equivalence or difference
Most randomised controlled trials test a hypothesis of a
difference between groups by disproving a null hypothesis
of no difference. In this trial, it is unlikely that PhysioDi-
rect would provide better clinical outcomes than usual
care in the long term. Instead the hypothesis is that Phys-
ioDirect would provide equally good clinical outcomes in
the long term, while being more cost-effective, providing
a faster recovery and return to work and providing impor-
tant benefits in secondary outcomes such as patient satis-
faction and waiting times. For this reason the study is
designed as an equivalence trial (to assess equivalence in
the primary outcome of clinical outcome at 6 months)
while also assessing difference in cost-effectiveness and
the secondary outcomes.
Appropriate outcome measures
In planning this study, there was much discussion about
the most appropriate primary outcome and how this
should be measured. It was decided to use clinical out-
come as the primary outcome for the reasons described
below. However, it could be argued that the main purpose
of this type of service is to improve cost-effectiveness, and
that effectiveness should not be considered without con-
sideration of cost. Just as it is important to consider
whether the extra cost of a new and more effective servicePage 8 of 11
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that a new service such as PhysioDirect may be justifiable
even if it is slightly less effective than usual care, if it is con-
siderably less expensive, and if the extra cost per QALY of
usual care is above the threshold used to determine the
acceptability of new treatments.
It was decided to use clinical outcome rather than cost-
effectiveness as the primary outcome for several reasons.
First, it is clearly important to establish whether a new
service is at least as effective as an existing service, and at
present (rightly or wrongly) it is conventional to assess
whether a new treatment is effective before considering
issues of cost-effectiveness. Second, the arguments
described above about the application of findings with
regard to cost-effectiveness are controversial [39]. Third,
there are various methodological issues relating to the use
of cost-effectiveness as a primary outcome which remain
unresolved or introduce large elements of uncertainty (for
example, assumptions needed to calculate sample size).
The traditional trial paradigm which places great empha-
sis on defining a primary outcome has limitations in rela-
tion to the evaluation of health service innovations. In
reality, policy decisions about the implementation of new
services will be based on taking into account all of the dif-
ferent benefits and costs. Different stakeholder groups
such as patients, health service managers or physiothera-
pists, will place different values on different outcomes (for
example, managers may place more value on cost and
patients on subjective experience).
Having decided to define clinical outcome as the primary
outcome, it was necessary to use a generic health measure
given the broad range of clinical conditions managed by
physiotherapists. Although there is a concern that generic
measures may be less responsive than disease specific
measures, the physical functioning and bodily pain scales
of the SF-36 (which contribute most of the variation in the
PCS summary measure used as the primary outcome in
this trial) compare reasonably well with disease specific
measures in patients with musculoskeletal problems [40-
43]. In addition, two further measures of clinical out-
come, one using a patient generated measure, are
included as important secondary outcomes to provide fur-
ther evidence about the equivalence (or otherwise) of the
two trial arms.
The use of mixed methods in evaluating a complex 
intervention
The introduction of PhysioDirect is a 'complex interven-
tion' with several components and possible 'active ingre-
dients'. In line with MRC guidance [44] the study will
combine quantitative, qualitative and economic methods
in order to understand how and why, as well as whether,
PhysioDirect is effective. Using mixed methods in this
way will make it possible to understand factors which act
as barriers and facilitators to the implementation of Phys-
ioDirect, and also key contextual factors which determine
the success or failure of this intervention.
It is important to note that the comparison between Phys-
ioDirect and usual care is not simply between a telephone
consultation versus a face-to-face consultation, nor is it
between an early telephone consultation versus a 'waiting
list control' i.e. receiving no care. It is between two differ-
ent care pathways, in one of which (PhysioDirect)
patients will receive earlier and more easily accessible
advice, mainly (but not entirely) by telephone, and in the
other pathway (usual care) patients will wait longer on
average for initial assessment which will always be face-to-
face, but they may have had some care by the time of first
outcome assessment. It is the use of telephone triage and
assessment that makes the early provision of advice possi-
ble: the issues of telephone based care and the earlier pro-
vision of care are inextricably linked and cannot be
separated in this pragmatic trial.
Conclusion
This pragmatic trial and associated qualitative research
and economic evaluation will provide robust evidence
about the benefits and costs of PhysioDirect services in
comparison to usual physiotherapy care. This will inform
decisions about the future implementation of these serv-
ices within the NHS, as well as providing wider lessons for
the development of other telephone based triage, assess-
ment and advice services in health care.
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